Precision Medical Ventures, Inc. Dba Revealdx

Seattle, WA, United States  All United States companies → — Founded 2021
Imaging AI Specialist Specialty-Focused AI
Oncology Pulmonology Radiology
Series B

Products

RevealAI-Lung
Precision Medical Ventures, Inc. Dba Revealdx
Oncology AI
RevealAI-Lung is an AI lung nodule characterization tool designed to support early lung cancer assessment by providing a Malignancy Similarity Index (mSI) score from CT scans.

See all 1 product →

About Precision Medical Ventures, Inc. Dba Revealdx

Precision Medical Ventures, Inc. Dba Revealdx (RevealDx) is a Seattle-based healthcare AI company focused on dramatically improving lung cancer outcomes through non-invasive diagnosis. They develop advanced, radiomics and AI-enabled, lung cancer decision support software. Their flagship product, RevealAI-Lung, is a Computer-Assisted Diagnostic (CADx) software that analyzes patient lung computed tomography (CT) images to provide information about lung nodules to radiologists.

RevealAI-Lung characterizes incidental lung nodules by generating a Malignancy Similarity Index (mSI), a score that assists radiologists in making more informed follow-up recommendations for cancer diagnosis. The software has been extensively validated in clinical trials, including studies with over 1,500 patients, demonstrating improved diagnostic precision and the ability to reduce false positives. It integrates directly into Picture Archiving and Communication Systems (PACS) to minimize disruption to radiology workflows and is reimbursable by U.S. Medicare under CPT codes 0721T and 0722T.S., MDR certification in Europe, and TGA approval in Australia.

Focus Areas

AI characterization of lung nodules radiomics lung cancer decision support software medical imaging AI precision medicine

Business Intelligence

TechnologyAI-enabled lung cancer decision support software, radiomics, machine learning, direct PACS integration, cloud-native

What Physicians Need to Know

Specialization
AI-powered lung cancer decision support software, focusing on the characterization of lung nodules using radiomics and machine learning.
Key Differentiator - Malignancy Similarity Index (mSI)
RevealDx's core technology, RevealAI-Lung, generates a Malignancy Similarity Index (mSI) score from CT scans to assess the risk of malignancy in lung nodules. This score aids radiologists in making more informed follow-up recommendations.
Key Differentiator - Non-Invasive Diagnosis
The company's mission is to dramatically improve lung cancer outcomes through non-invasive diagnosis, which is particularly important given the high morbidity and mortality rates associated with lung biopsies and surgeries.
Key Differentiator - Improved Diagnostic Accuracy
Clinical studies have shown that RevealAI-Lung significantly improves radiologists' accuracy in diagnosing pulmonary nodules, with one study demonstrating an average improvement of 18 points (from 0.54 to 0.72 AUC).
Key Differentiator - Reduced Unnecessary Procedures & Early Diagnosis
The technology aims to reduce unnecessary procedures and accelerate lung cancer diagnosis. It has the potential to identify up to 45% of malignant nodules when they first appear, reducing delayed cancer diagnoses.
Technology Stack - AI and Machine Learning
RevealDx leverages advanced radiomics and AI, specifically machine learning techniques, to analyze chest CT scans and characterize lung nodules.
Technology Stack - Proprietary Analytics
The software employs proprietary analytics, including a patented approach that provides improved stability across image types and transparency of predictions. It extracts local predictive value from 3D analysis of lesions and enhances results with broader lung and chest analysis.
Regulatory Clearances
RevealAI-Lung has received FDA clearance in the US, MDR Certification in Europe, and TGA approval in Australia.
Reimbursement
In the US, RevealAI-Lung is reimbursable under Medicare Outpatient Prospective Payment System (OPPS) using Category III CPT codes 0721T and 0722T, at a rate of approximately $650.
Clinical Validation
The software has been extensively validated in clinical trials and years of research, including validation on over 1,500 patients from various cohorts.
Physician Tip

For physicians, RevealDx's RevealAI-Lung offers a powerful tool to enhance lung nodule assessment. The Malignancy Similarity Index (mSI) provides objective, AI-driven insights to aid in distinguishing benign from malignant nodules, potentially leading to earlier cancer diagnoses and reducing unnecessary invasive procedures. The software's direct integration into PACS systems streamlines workflow, allowing for single-click operation and rapid results. This augmentative technology uncovers radiomic biomarkers invisible to the human eye, adding significant value to radiologists' decision-making process and ultimately improving patient outcomes and potentially reducing healthcare costs.

RevealDx's RevealAI-Lung is designed for direct integration into Picture Archiving and Communication Systems (PACS), aiming to minimize disruption to radiologists' existing workflows. They have announced integrations with Riverain, Fujifilm PACS, and Sirona Medical's cloud-native radiology workflow platform. Additionally, a partnership with 4DMedical will embed RevealAI-Lung into their contextflow chest CT platform, combining AI risk scoring with functional lung physiology.

Products by Precision Medical Ventures, Inc. Dba Revealdx

1 product in the directory

RevealAI-Lung
Precision Medical Ventures, Inc. Dba Revealdx
Oncology AI
RevealAI-Lung is an AI lung nodule characterization tool designed to support early lung cancer assessment by providing a Malignancy Similarity Index (mSI) score from CT scans.

Videos

News, demos, and interviews about Precision Medical Ventures, Inc. Dba Revealdx.

Loading videos...

Videos load interactively. If none appear, search YouTube for Precision Medical Ventures, Inc. Dba Revealdx →

View all on YouTube

No press coverage or publications on file yet. Know of some? Suggest an edit →

Frequently Asked Questions

Revealdx leverages advanced AI, including deep learning and radiomics, to analyze medical images for lung nodule characterization. This technology extracts quantitative features from imaging data that are often imperceptible to the human eye, aiming to provide more objective and precise assessments of nodule malignancy risk, thereby enhancing diagnostic accuracy and potentially reducing unnecessary invasive procedures.
Revealdx's lung cancer decision support software is designed for seamless integration with existing PACS (Picture Archiving and Communication Systems) and EMR (Electronic Medical Record) systems through standard protocols like DICOM and HL7. This integration allows for automated data transfer and analysis, providing clinicians with timely, AI-powered insights directly within their established workflows, which can streamline decision-making and improve efficiency without significant disruption.
Revealdx is committed to demonstrating the clinical efficacy and cost-effectiveness of its AI solutions through rigorous validation studies and real-world data analysis. Our solutions aim to improve patient outcomes by enabling earlier and more accurate diagnoses, potentially reducing healthcare costs associated with delayed or incorrect diagnoses and unnecessary interventions.
Revealdx offers flexible pricing models tailored to the needs of different healthcare institutions, which can include subscription-based licensing or per-study fees. We provide comprehensive technical support, including dedicated account management, 24/7 technical assistance, and ongoing training programs for medical staff to ensure optimal utilization and integration of our AI solutions.
Revealdx prioritizes regulatory compliance and data privacy, adhering to stringent standards such as FDA regulations, CE Mark requirements, HIPAA, and GDPR. Our products undergo rigorous testing and validation, and our data handling practices are designed to ensure the highest levels of security and patient confidentiality.
Revealdx's long-term vision extends beyond lung cancer to encompass AI-powered diagnostic and decision support solutions for a broader range of cancer types and medical conditions. Our product roadmap includes continuous innovation in AI algorithms, expansion into new imaging modalities, and the development of integrated platforms that support comprehensive precision medicine initiatives across various specialties.
Revealdx is a stable and growing company with a strong foundation in medical AI innovation. We have established strategic partnerships with leading academic institutions, medical device manufacturers, and technology providers to further enhance our research and development capabilities, expand our market reach, and ensure the seamless integration of our solutions within the healthcare ecosystem.

Related Companies

Spectrum Dynamics Medical is a pioneering medical device company focused on transforming nuclear medicine from analog to digital technology. They specialize in developing high-definition, solid-state based nuclear imaging technology, including digital SPECT (Single Photon Emission Computed Tomography) and SPECT/CT systems. Their products aim to meet the clinical needs and workflow demands of diagnostic imaging departments […]

Siemens Medical Solutions USA, Inc., operating as Siemens Healthineers USA, is a prominent medical technology company with a rich history spanning over 175 years, dedicated to pioneering breakthroughs in healthcare. As a subsidiary of the global Siemens Healthineers AG, the company offers a comprehensive portfolio that is central to clinical decision-making across the entire healthcare […]

Siemens Healthineers is a leading global medical technology company that pioneers breakthroughs in healthcare. The company focuses on medical technology and diagnostics, offering a wide range of products including imaging systems, laboratory diagnostics, and advanced therapies. Their innovations aim to improve patient outcomes and make healthcare more accessible and sustainable. Siemens Healthineers has a strong […]

Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]

Varian Medical Systems, now a Siemens Healthineers company, is a global leader in advanced radiation oncology solutions for comprehensive cancer treatment. The company develops and manufactures medical devices and software for treating cancer and other medical conditions using therapies such as radiotherapy, radiosurgery, proton therapy, and brachytherapy. Their product portfolio includes linear accelerators (LINACs), proton […]

Philips Healthcare (Suzhou) Co., Ltd. is a Chinese subsidiary of the multinational health technology company Philips, specializing in AI-enabled medical imaging and radiology workflow software. The company focuses on developing systems and software designed to streamline radiology workflows and enhance clinical insights through AI and data analytics. This includes AI-enabled imaging systems, intelligent software, imaging […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.